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Abstract
Patients with carcinoid tumours frequently present with metastatic disease. There are only a few therapeutic options for these patients,
and the main goal of palliative treatment is to reduce symptoms and thus to improve quality of life. Current therapy includes surgical
resection, hepatic artery embolisation, chemotherapy and somatostatin analogue treatment; however, all these options have limitations. It
seems probable that therapeutic modalities based on radiopharmaceuticals may provide better therapy, not only in relation to symptom
reduction but may also improve patient survival.
In this case report we present a 46-year-old woman with a symptomatic carcinoid, who at the time of diagnosis had liver and abdominal
lymph node metastases, the primary tumour being located in the terminal ileum. 111In-pentetreotide scanning was negative, whereas
123I-MIBG scanning showed high avidity in the tumour tissue. After right hemicolectomy, two courses of 131I-MIBG treatment were given
(12.95 GBq and 12 GBq, respectively). After the second dose of 131I-MIBG temporary pancytopenia was present. Octreotide therapy was
given empirically only for a short time and was stopped because of drug intolerance. The patient underwent tricuspid and pulmonary
valve replacement because of her carcinoid heart disease, followed by two courses of embolisation of liver metastases. While 131I-MIBG
therapy reduced the patient’s symptoms of flushing and diarrhoea, there has not yet been any effect on tumour response or 5-HIAA
production. This case illustrates the multimodality and multidisciplinary approach to such patients. (Pol J Endocrinol 2008; 59 (4): 342–347)
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Streszczenie
U chorych z rakowiakiem często występują przerzuty. W takich przypadkach istnieje niewiele opcji terapeutycznych. Głównym celem
leczenia paliatywnego jest złagodzenie objawów i poprawienie jakości życia. Dostępne obecnie metody terapii obejmują chirurgiczną
resekcję zmian nowotworowych, embolizację tętnicy wątrobowej, chemioterapię i stosowanie analogów somatostatyny. Jednak wszyst-
kie te metody mają ograniczenia. Wydaje się, że stosując techniki radiofarmakologiczne można uzyskać najlepsze rezultaty, nie tylko pod
względem zmniejszenia objawów, ale również wydłużenia okresu przeżycia.
W niniejszej pracy autorzy opisują przypadek 46-letniej kobiety z objawowym rakowiakiem, u której w chwili rozpoznania choroby
stwierdzono przerzuty do węzłów wątroby oraz brzusznych węzłów chłonnych. Guz pierwotny znajdował się w końcowym odcinku
jelita krętego. W badaniu radioizotopowym z użyciem 111In-pentetreotydu nie wykazano gromadzenia radioznacznika, natomiast w scynty-
grafii z użyciem 123I-MIBG stwierdzono zwiększony wychwyt znacznika przez tkanki guza. Po wykonaniu prawostronnej hemikolektomii
zastosowano dwa cykle terapii 131I-MIBG (odpowiednio: 12,95 i 12 GBq). Po drugiej dawce 131I-MIBG wystąpiła okresowa pancytopenia.
Zastosowano empirycznie terapię okreotydem, jednak przerwano ją po krótkim czasie z uwagi na nietolerancję leku. Chora przebyła
zabieg wymiany zastawek trójdzielnej i płucnej z powodu rakowiakowej choroby serca, a następnie 2-krotną embolizację przerzutów
wątrobowych. Chociaż terapia 131I-MIBG spowodowała złagodzenie objawów, napadowego przekrwienia skóry i biegunki, jednak nie
zaobserwowano zmniejszenia guza ani ograniczenia produkcji 5-HIAA. Opisany przypadek jest przykładem multimodalnego i wielody-
scyplinarnego leczenia rakowiaka. (Endokrynol Pol 2008; 59 (4): 342–347)
Słowa kluczowe: rakowiak, choroba przerzutowa, leczenie paliatywne
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Introduction
Gastro-enteric neuroendocrine tumours (NETs), formerly
known as carcinoids, appear to have increased in overall
incidence over the past 30 years. In spite of improved
diagnostic technology and increased awareness, patients
with such tumours still frequently present with metasta-
tic disease [1, 2]. In addition, carcinoid heart disease
(CHD) appears in more than half of the patients with the
carcinoid syndrome, and remains a major cause of mor-
bidity and mortality among these patients [3, 4].
There are relatively few therapeutic options for wi-
dely metastatic carcinoids, and the main aim of this tre-
atment is to reduce the symptoms related to hormone
excess and to prolong survival. Palliative therapy inclu-
des surgical resection, hepatic artery embolisation, im-
munomodulatory therapy (principally interferon) and
octreotide treatment; chemotherapy plays only a limi-
ted role. It is apparent that new therapeutic modalities
based on radiopharmaceuticals e.g. 131I-MIBG (Iodine-131
metaiodobenzylguanidine) and radolabelled octreotide
may provide better therapeutic possibilities in selected
patients with metastatic carcinoid, not only in relation to
symptom reduction but also long-term survival [5].
In this case report, we present a patient with a symp-
tomatic carcinoid who was initially diagnosed with me-
tastatic disease with primary localisation in the termi-
nal ileum, complicated by carcinoid heart disease, who
underwent complex treatment including right hemico-
lectomy, 131I-MIBG therapy, embolisation of liver meta-
stases, and tricuspid and pulmonary valve replacement.
We demonstrate the modern multimodality treatment
of this difficult condition, and the fact that 131I-MIBG
therapy has appeared to reduce the patient’s symptoms,
although with little effect on tumour bulk so far.
Case report
A 47-year-old dental nurse was first seen in the Depart-
ment of Endocrinology, St. Bartholomew’s Hospital in
London, in January 2006. Her previous medical history
started in 2003, when she suffered night sweats and flu-
shing; she disregarded these symptoms believing that they
were related to her imminent menopause. Her family and
social history was unremarkable, she had three healthy
children, never drank alcohol and had never smoked.
In 2004 she had visited her General Practitioner (GP)
for a routine cervical smear, which showed mild dys-
plasia. In 2005 she returned to GP for a repeat smear
test. During routine examination her blood pressure was
found to be elevated (196/103 mm Hg), and she was star-
ted on anti-hypertensive medications. Despite different
treatment combinations, her blood pressure control was
not satisfactory (234/122, 218/166 mm Hg). She develo-
ped intermittent diarrhoea, which was attributed at that
time to treatment side effects. She was referred to a spe-
cialist in hypertension, who investigated her seconda-
ry causes of hypertension. Her renal magnetic resonance
angiography showed normal renal arteries but her ri-
ght kidney was displaced by an enlarged liver with
multiple focal masses, present in both lobes. Because
her initial blood tests had revealed hypokalaemia
(3.2 mmol/L) and an elevated aldosterone/renin ratio
(50.7 and 79 ng/mu, normal range 0–25 ng/mu), she was
referred for further specialist endocrine investigation.
Subsequent blood tests showed elevated serum
chromogranin A (> 1000 pmol/L, normal range: 0–
–60 pmol/L) and 24-urine 5-HIAA (5-hydroxyindoleacetic
acid) excretion (876 mmol/24 h, normal range: 9-31 mmol/
/24 h). An abdominal CT scan with contrast showed
multiple focal masses throughout the liver with normal
adrenal glands, a 3cm mass high and anterior in the left
abdomen, and an eccentric lesion in a loop of small bo-
wel below the right kidney. CT-guided biopsy of the
liver lesion established a diagnosis of metastatic neuro-
endocrine tumour (immunohistochemistry showed
positive chromogranin, CD56, neuron-specific enolase
and Cam 5.2 staining). In December 2005 she was refer-
red to our Department.
During her first admission in our Department in Ja-
nuary 2006, she was reported to be suffering from diar-
rhoea and flushing. Investigations at this time revealed
normal plasma neuroendocrine peptide concentrations
and normal 24-urine catecholamine collections. Her 24-
urine 5-HIAA was elevated and even higher than in 2005
(2132 mmol/24 h; Figure 1). An 111In-pentetreotide scan
Figure 1. Urine 5-HIAA 24-hour measurements performed
between January 2006 and May 2007 in Barts and the London
Hospital
Rycina 1. Oznaczenie zawartości 5-HIAA w dobowej zbiórce
moczu. Badania wykonano w Barts and the London Hospital
w okresie od stycznia 2006 do maja 2007 roku
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(OctreoScanTM) showed no evidence of somatostatin
receptor expression; however, 123I-MIBG showed mul-
tiple 123I-MIBG avid in both lobes of the liver and in the
mass in the left upper abdomen. Echocardiography
(ECHO) demonstrated very mild tricuspid regurgita-
tion (TR). Isotope bone scan was normal.
The patient was discussed at a multi-disciplinary
team meeting and it was decided to remove the ileac
primary lesion. In February 2006 right hemicolectomy
was performed. A carcinoid tumour in the terminal
ileum was resected, histologically showing vascular and
perineural invasion, and with multiple mesenteric
lymph nodes (6 of 21 examined showed tumour) and
liver metastases.
In April 2006 she was admitted for the first dose of
131I-MIBG treatment (12.95 GBq; 350 mCi). Treatment
with 131I-MIBG was performed on an inpatient basis.
Before 131I-MIBG, the patient was given potassium io-
dide to block thyroid accumulation of radioiodine. A
repeated echocardiogram reported progression in the
tricuspid regurgitation with borderline right ventricle
systolic pressure overload (RVSP — 37 mm Hg).
In July 2006 she was admitted for re-assessment. She
now complained of increasing breathlessness, princi-
pally on exertion but without associated chest pain, and
also persistent peripheral oedema; she had developed
gradual deterioration in her exercise tolerance. Howe-
ver, her flushing and diarrhoea following the first dose
of 131I-MIBG therapy were well controlled. Her routine
blood investigations and 24-urine 5-HIAA collection
were stable (Table 1; Figure 1). A CT of the chest and
abdomen/pelvis showed multiple liver metastases with
a small amount of free fluid in the abdomen and pelvis,
which was thought to represent peritoneal disease, but
the size of the lesions appeared stable. She received
a second course of 131I-MIBG (12 GBq; 324 mCi). A repe-
at 131I-MIBG post-therapy scan showed 131I-MIBG upta-
ke in the liver and in the upper abdomen (Figure 2).
Compared to the previous scan, there appeared to be
some increased activity in the upper mild abdomen, but
without any clear evidence of disease progression.
A B
Table I. Neuroendocrine markers results
Tabela I.  Stężenia markerów neuroendokrynnych
Jan 2006 Jul 2006 Normal range Unit
Plasma
Gastrin 14 8 0–40 pmol/L
VIP < 4 3 0–30 pmol/L
PP 22 30 0–300 pmol/L
Glucagon 6 < 5 0–50 pmol/L
Somatostatin 30 36 0–150 pmol/L
Neurotensin 56 22 0–100 pmol/L
Chromogranin A > 1000 0–60 pmol/L
Chromogranin B 156 0–150 pmol/L
Urine
Adrenaline < 30 < 30 0–560 nmol/24 h
Noradrenaline 212 205 0–560 nmol/24 h
Dopamine 928 941 0–3194 nmol/24 h
5-HIAA 2049 2162 0–50 umol/24 h
Figure 2. A repeated 131I-MIBG post-therapy scan
Rycina 2. Powtórna scyntygrafia po terapii 131I-MIBG
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In July 2006, in spite of a negative octreotide scinti-
scan, octreotide therapy was started (100 mg twice a day),
but this was poorly tolerated and stopped.
A repeat echocardiogram performed in July 2006
showed severe tricuspid regurgitation: the right ven-
tricle was moderately dilated with a mild reduction in
systolic function; the right atrium was also moderately
dilated. In a right ventricular angiogram, ventricular,
atrial and pulmonary artery pressures were 37/15,
24 and 30/11 mm Hg, respectively. In view of the pro-
gression of echocardiographic abnormalities and incre-
asing symptoms, the patient was now considered su-
itable for appropriate valve replacement. However, at
this point (August 2006) the procedure was postponed
because of sever pancytopenia, occurring four weeks
after the second course of 131I-MIBG (Figure 3). The pa-
tient required repeated platelet and blood transfusions,
but by January 2007 her haematological parameters had
improved sufficiently for her to undergo tricuspid and
pulmonary valve replacement. Two tissue grafts were
inserted (in order to obviate the need for anti-coagula-
tion), and she rapidly noted an improvement in her
exercise tolerance.
Over the next few months she remained well, but
due to a persisting very high level of 5-HIAA, which
was not improved by 131I-MIBG therapy, further thera-
peutic options for liver metastases were discussed. In
May 2007 she had embolisation of liver metastases, com-
plicated by a transient right unilateral hemianopia.
Magnetic resonance of the brain did not show any alte-
ration; she was started on 75 mg of aspirin and dischar-
ged home in a good general condition. She has rema-
ined well, but in view of the stable but elevated level of
urinary 5-HIAA she underwent a second hepatic artery
embolisation in February 2008.
She continues to be well with good exercise toleran-
ce and no further flushing or diarrhoea. She is curren-
tly taking amiloride, bisoprolol, valsartan, furosemide
and codeine phosphate.
Discussion
Carcinoid tumours represent an unusual and complex
disease spectrum with protean clinical manifestations
[2]. Because many of the symptoms are relatively non-
specific, the diagnosis of this disease remains proble-
matic, and many carcinoids are diagnosed late with
metastatic complications. Within the gastrointestinal
tract, most carcinoid tumours originate in the small in-
testine (41.8%), but also derive from the rectum (27.4%)
and stomach (8.7%). The highest percentages of non-
localised lesions are noted for caecal (81.5–83.2%) and
pancreatic (71.9–81.3%) carcinoids, whereas the highest
Figure 3. Blood account assessed between January 2006 and May
2007 in Barts and the London Hospital
Rycina 3. Wyniki badania krwi wykonane w Barts and the
London Hospital w okresie od stycznia 2006 do maja 2007
percentage of localised disease is found among rectal
(81.7%), gastric (67.5%), and bronchopulmonary (65.4%)
carcinoids [2].
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Neuroendocrine tumours (NETs) may express acti-
ve amine precursor uptake-1 mechanisms and/or spe-
cific receptors at the cell membrane, and therefore can
be detected and treated with the use of radiopharma-
ceuticals reliant upon these specific mechanism [6]. Ra-
diolabelled octreotide, an analogue of somatostatin, is
used in vivo to demonstrate tumours that have soma-
tostatin receptors on their surface, which is important
both diagnostically as well as therapeutically. 111In-pen-
tetreotide remains the principal radiodiagnostic soma-
tostatin analogue [6, 7], although other novel analogu-
es are currently under trial. On the other hand,
123I-MIBG is an alkyl-guanidine derivative that is similar
to noradrenaline and is accumulated by tissues thought
to arise from neural crest cells; 123I-MIBG has been shown
to be highly sensitive for detecting tumours arising from
the adrenal medulla but may be also taken up by non-
adrenomedullary NETs [6, 7]. A direct comparison of
111In-pentetreotide and 123I-MIBG scintigraphy perfor-
med in the same group of advanced NET patients sho-
wed that octreotide scanning was more sensitive in
detecting metastatic lesions (as demonstrated on com-
puter tomography and/or magnetic resonance) than
123I-MIBG for carcinoid tumours, pancreatic islet cell tu-
mours and medullary thyroid carcinomas, whereas
123I-MIBG was superior to 111In-pentetreotide for pha-
eochromocytomas and paragangliomas [6].
In our case of metastatic carcinoid, 111In-pentetreoti-
de was negative while 123I-MIBG showed high avidity
for tumour tissue. It has been reported that 111In-pente-
treotide was positive more frequently than 123I-MIBG
scanning in the group of 24 patients with carcinoids
(67% vs. 50%, respectively), with few patients showing
uptake with 123I-MIBG not present with radiolabelled
octreotide. However, there were also exceptions to this,
since two cases were found to be 111In-pentetreotide-
negative and 123I-MIBG positive, and our patient con-
firms that this pattern can occur and be therapeutically
relevant [6].
The therapeutic modalities for advanced carcinoids
include palliative surgery, hepatic artery embolisation,
chemotherapy, immunomodulatory therapy and/or
somatostatin analogue treatment, and more recently
radiopharmaceutical therapy.
Our patient underwent right hemicolectomy and
removal of the apparent primary tumor, which allowed
full histological assessment. While in some more mali-
gnant diseases such removal of the primary in the pre-
sence of metastases is contraindicated, for many NETs
this tumour debulking may be useful in its own right,
in terms of tumour bulk reduction to increase the effec-
tiveness of other adjuvant therapies, as well as decre-
asing the likelihood of intestinal obstruction. Further
therapy with 131I-MIBG treatment was chosen based on
high 123I-MIBG tumour avidity: the patient received two
courses of 131I-MIBG therapy, the doses being based on
a dose-finding study to assess maximal marrow tolera-
bility, with a cumulative dose of 24.95 GBq (~ 680 mCi).
Pancytopenia related to the second dose of 131I-MIBG
precluded further 131I-MIBG treatment, and led to
a delay in the replacement of her cardiac valves. Howe-
ver, recent studies have suggested that small numbers
of high doses of 131I-MIBG are the most likely to lead to
clinical improvement.
131I-MIBG treatment was found to be a good palliati-
ve therapeutic option for metastatic carcinoid, with re-
sponse rates of 40–60% [8–10]. In a retrospective analy-
sis performed by Safford and colleges, the results of
131I-MIBG therapy were analysed in a group of 98 patients
with metastatic carcinomas, whose 123I-MIBG scans per-
formed before treatment showed abnormal accumula-
tion in the site of known disease. In this study, the end-
points examined included the World Health Organiza-
tion criteria for treatment response: symptoms, 5-HIAA
production, and clinical tumour response. 69, 20 and
4 patients received one, two or three dose of 131I-MIBG,
respectively, the mean dose of 131I-MIBG being 401 ±
± 202 mCi. They found that patients who experienced
a symptomatic response after 131I-MIBG also showed im-
proved survival (5.76 years vs. 2.09 years, P < 0.01), but
neither the reduction in 5-HIAA levels nor radiographic
tumour response after 131I-MIBG treatment predicted
survival. Survival improvement was related to 131I-MIBG
dose because patients who received an initial 131I-MIBG
dose > 400 mCi lived longer than patients who received
< 400 mCi (4.69 years vs. 1.86 years; P = 0.05) [5]. It is
well established that 131I-MIBG therapy might be asso-
ciated with several complications, of which bone mar-
row suppression (including pancytopenia or thrombo-
cytopenia) remains the most frequent, occurring in
13% of patients [5]. Other toxicities include nausea and eme-
sis. It appears that such complications are not related to the
dose level or the number of doses of 131I-MIBG [5].
A short course of octreotide was given, in spite of
111In-pentetreotide-scan negativity, but this was stop-
ped due to poor tolerance. While the 131I-MIBG therapy
was not associated with any clear fall in urinary 5-HIAA
secretion or tumor regression, the patient did show an
improvement in her symptoms. She was finally treated
with hepatic embolisation with microspheres on two
occasions, and this was well tolerated. It was decided
not to use chemo-embolisation as this has not been cle-
arly shown to be superior to simple embolisation alone,
and the patient’s bone marrow had already been com-
promised by the radiolabelled therapy.
As yet we have not utilized systemic chemothera-
py. Chemotherapy in NETs can be associated with
symptomatic and hormonal improvement and, very
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occasionally, tumour regression or stabilization; howe-
ver, long-term survival remains poor. The current role
of chemotherapy seems to be for well-differentiated
carcinoids and particularly islet-cell tumours showing
progression of the disease after treatment with soma-
tostatin analogues or radiopharmaceuticals [11].
Another challenge in carcinoid patient care is rela-
ted to carcinoid heart disease (CHD) management. CHD
is a relatively rare form of valvular heart disease; howe-
ver, it appears in more than half of patients with carci-
noid syndrome [12]. It typically occurs when tumour
progression results in the formation of hepatic meta-
stases which allow vasoactive substances to reach the
heart without being metabolized in the liver. The only
exception in which CHD was not related to liver invo-
lvement has been reported in patients with primary
ovarian carcinoid tumours [13]. The concentration of
circulating serotonin and the urinary excretion of
5-HIAA have been shown to be higher among patients
with CHD than among patients without cardiac invo-
lvement [14]. Furthermore, urinary 5-HIAA levels have
been associated with progression of CHD [15].
Cardiac surgery has been recognised as the only ef-
fective treatment option in the group of patients with
severe cardiac involvement and well-controlled syste-
mic disease [16]. The current indications for cardiac va-
lve replacement include symptoms of right ventricular
failure with progressive fatigue, significantly impaired
exercise capacity, progressive right ventricular enlarge-
ment and decline in right ventricular systolic function.
Valve replacement surgery may not only be beneficial
in terms of symptom relief, but may contribute to the
improved survival. It seems that early diagnosis and
early surgical treatment in appropriately selected pa-
tients may provide the best results [12].
Our patient underwent successful tricuspid and
pulmonary valve replacement, which improved right
ventricular failure and exercise tolerance. Because
131I-MIBG therapy did not stop or even decrease high
5-HIAA secretion, she underwent embolisation of liver
metastases in order to avoid further cardiac problems
related to exposure to vasoactive substances produced
by the carcinoid tumour. In the future, further eviden-
ce of progression will lead to consideration of more
experimental therapies, such as the chemotherapy agent
temozolomide and the ‘mTOR’ inhibitor everolimus
(RAD001, Novartis).
In conclusion, we have presented a case in which
a metastatic NET has been aggressively treated with sur-
gery, 131I-MIBG therapy and hepatic artery embolisa-
tion, as well as with surgical replacement of the tricu-
spid and pulmonary vales with tissue grafts. This case
emphasizes the importance of assessing such patients
with a multi-disciplinary team, and the importance of
the availability of multimodality therapies both to im-
prove survival, where possible, and to increase the qu-
ality of life in patients with indolent disease.
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